Biologics CDMO Market Summary

Overview
• The Biologics CDMO market is estimated at USD 23.00 billion in 2025 and is projected to reach USD 62.00 billion by 2034. Growth is anchored in the expanding biologics pipeline, rising outsourcing by pharmaceutical and biotechnology companies, and a wave of large-scale capacity investment and consolidation among leading contract developers and manufacturers.
• The global Biologics CDMO market is growing at a CAGR of 11.7% during the forecast period from 2026 to 2034.
• By product type, the monoclonal antibodies segment dominated the Biologics CDMO market with a 57% share in 2025.
• By service type, the contract manufacturing segment dominated the Biologics CDMO market with a 58% share in 2025.
• By source, the mammalian expression segment dominated the Biologics CDMO market with a 70% share in 2025.
• By indication, the oncology segment dominated the Biologics CDMO market with a 40% share in 2025.
• North America dominated the global Biologics CDMO market revenue with a 42% share in 2025, representing the highest regional market share globally.
A biologics contract development and manufacturing organization (CDMO) provides outsourced development, manufacturing, and related services for biologic medicines, including monoclonal antibodies, recombinant proteins, vaccines, antibody-drug conjugates, and cell and gene therapy products. Biologics CDMOs support pharmaceutical and biotechnology companies across the value chain, from cell-line development, process and analytical development, and clinical-scale supply to commercial drug-substance and drug-product manufacturing, fill-finish, packaging, and quality and regulatory services. Production relies on living systems, predominantly mammalian cell culture and, for certain proteins, microbial fermentation, and demands specialized facilities, single-use and stainless-steel bioreactors, rigorous quality systems, and deep regulatory expertise. By outsourcing to CDMOs, drug developers access specialized capabilities and large-scale capacity without heavy capital investment, accelerate time to market, and manage the complexity of novel modalities. The market spans contract development and contract manufacturing services, mammalian and microbial expression systems, and applications across oncology, immunology, infectious disease, and other therapeutic areas. Propelled by a growing biologics and biosimilar pipeline, rising outsourcing penetration, the ADC and cell-and-gene-therapy boom, and substantial capacity expansion and consolidation, biologics CDMOs have become indispensable infrastructure for the global biopharmaceutical industry.
Biologics CDMO Market Key Growth Drivers
• The expanding biologics pipeline, led by monoclonal antibodies, antibody-drug conjugates, and cell and gene therapies, is increasing demand for specialized development and manufacturing capacity.
• Rising outsourcing by pharmaceutical and biotechnology companies, now estimated at 40% of pharmaceutical manufacturing, is shifting biologics production to CDMOs to access expertise and capacity without heavy capital investment.
• The rising global cancer burden is driving demand for oncology biologics, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050.
• The growth of biosimilars, as major biologics lose exclusivity, is expanding manufacturing demand for high-volume, cost-competitive production.
• Large-scale capacity investment and consolidation, including multi-billion-dollar acquisitions and new plants, are expanding global biologics manufacturing supply.
• Emerging biotechnology companies, which often lack in-house manufacturing, increasingly rely on CDMOs to advance programs and shorten time to market.
• The convergence of pipeline growth, outsourcing, oncology and biosimilar demand, and capacity expansion is expected to sustain strong double-digit growth in the market through 2034.
Key Companies in Biologics CDMO Market
The competitive landscape is led by the following active developers and manufacturers:
• Lonza Group AG
• Samsung Biologics Co., Ltd.
• WuXi Biologics (Cayman) Inc.
• Catalent, Inc.
• Thermo Fisher Scientific Inc.
• FUJIFILM Diosynth Biotechnologies
• Boehringer Ingelheim (BioXcellence)
• AGC Biologics
• Rentschler Biopharma SE
• Syngene International Limited
Factors Contributing to the Growth of the Biologics CDMO Market
Market Drivers
Expanding Biologics and Advanced-Modality Pipeline
The most powerful driver of the Biologics CDMO market is the expanding pipeline of biologic medicines and advanced modalities. Monoclonal antibodies remain the largest and fastest-growing class, while antibody-drug conjugates, bispecific antibodies, recombinant proteins, vaccines, and cell and gene therapies are proliferating across clinical and commercial pipelines. These products are complex to develop and manufacture, requiring specialized expression systems, bioreactors, conjugation and fill-finish capabilities, and rigorous quality and regulatory expertise that many developers do not hold in-house. As the number and diversity of biologics in development grow, demand for outsourced development and manufacturing capacity rises in parallel, and the shift toward novel modalities raises the technical bar in ways that favor specialized CDMOs. This deep and broadening pipeline, spanning antibodies through cell and gene therapies, anchors sustained demand for biologics CDMO services through the forecast period. 
Rising Outsourcing by Pharmaceutical and Biotechnology Companies
Rising outsourcing is a central growth engine, as pharmaceutical and biotechnology companies increasingly shift biologics development and manufacturing to CDMOs. Outsourcing now accounts for an estimated 40% of pharmaceutical manufacturing, and the share is higher and rising for complex biologics. Faced with high capital costs, complex and uncertain pipelines, and pressure to accelerate time to market, developers turn to CDMOs to access specialized expertise, advanced technologies, and large-scale capacity without committing to heavy fixed investment in plants that may sit underused if a program fails. Outsourcing converts capital expenditure into variable cost, de-risks capacity decisions, and provides flexibility across modalities and scales. Emerging biotechnology companies in particular depend on CDMOs to manufacture clinical and commercial supply. As outsourcing penetration deepens across the industry, demand for biologics CDMO services expands steadily, reinforcing market growth across the forecast period. 
Market Restraints
Despite strong momentum, the Biologics CDMO market faces material constraints. High capital intensity is a defining challenge, as building and operating biologics facilities requires enormous investment in bioreactors, clean-room infrastructure, single-use systems, and quality systems, and capacity decisions carry significant risk, since plants can sit underused if client pipelines slip or programs fail, while shortages can constrain growth when demand surges. Long facility construction and validation timelines, often spanning several years, limit how quickly supply can respond to demand. A shortage of skilled biomanufacturing talent, including process scientists, engineers, and quality professionals, constrains expansion and raises staffing and validation risk at new sites. Stringent and evolving regulatory requirements across the United States, Europe, and Asia demand rigorous quality systems, comparability, and ongoing inspection readiness, lengthening timelines and raising the cost of compliance. Client concentration and dependence on a limited number of large programs expose CDMOs to revenue volatility if contracts are lost or delayed. Geopolitical and trade dynamics, including supply-chain dependencies, reshoring pressures, tariffs, and proposed biosecurity legislation affecting certain manufacturers, add uncertainty and may reshape sourcing. Pricing pressure in competitive segments such as biosimilars compresses margins, and overcapacity in some modalities can intensify competition. Together, these capital, talent, regulatory, concentration, and geopolitical barriers temper the pace of growth, even as the underlying drivers of pipeline expansion and outsourcing remain firmly intact.
 
Biologics CDMO Market Segment Analysis
The Biologics CDMO Market by Product Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Antibody-Drug Conjugates, Cell and Gene Therapy Products, Other Biologics), Service Type (Contract Manufacturing, Contract Development, Analytical and Quality Services, Fill-Finish and Packaging), Source (Mammalian, Microbial, Other Expression Systems), Indication (Oncology, Autoimmune and Inflammatory, Infectious Diseases, Metabolic, Others), and Geography (North America, Europe, Asia-Pacific, Rest of World).
By Product Type
Dominant Subsegment: Monoclonal Antibodies. The monoclonal antibodies category is expected to dominate the market.
Dominant:  Monoclonal Antibodies ~ 57%
The monoclonal antibodies segment accounted for 57% of the Biologics CDMO market in 2025. Monoclonal antibodies are the leading product type because they represent the largest and most established class of biologics by revenue and pipeline, spanning oncology, immunology, and infectious disease, and because they require large-scale mammalian manufacturing that CDMOs are well positioned to provide. The high and growing volume of approved and pipeline antibodies, including a broad biosimilar wave as reference products lose exclusivity, sustains substantial demand for drug-substance and drug-product manufacturing. Antibodies also anchor the largest capacity investments by leading CDMOs, reflecting their central role in outsourced biologics production. Adjacent classes are growing quickly, with antibody-drug conjugates and bispecifics expanding rapidly from a smaller base and cell and gene therapy products representing the fastest-growing and most strategically important modality, while recombinant proteins and vaccines remain significant. Nonetheless, the scale, maturity, and biosimilar tailwind of monoclonal antibodies secure their clear leadership across the forecast period.
By Service Type
Dominant Subsegment: Contract Manufacturing. The contract manufacturing category is expected to dominate the market.
Dominant:  Contract Manufacturing ~ 58%
The contract manufacturing segment accounted for 58% of the Biologics CDMO market in 2025. Contract manufacturing is the leading service type because commercial and clinical drug-substance and drug-product manufacturing represents the largest, most capital-intensive, and highest-value portion of the biologics CDMO value chain. Manufacturing generates recurring, volume-linked revenue across long-term supply agreements, and the scale of investment in bioreactor capacity by leading CDMOs underscores its dominance. As biologics move from development into commercial supply and as biosimilars demand high-volume, cost-competitive production, manufacturing demand expands. Contract development, including cell-line, process, and analytical development, is essential and fast-growing as it feeds the manufacturing pipeline and anchors long-term client relationships, while analytical and quality services and fill-finish and packaging are critical adjacent segments, with fill-finish capacity a particular focus of recent investment. While development and specialized services grow rapidly, the scale, recurring economics, and capacity intensity of contract manufacturing secure its leadership across the forecast period.
Biologics CDMO Market Region Analysis
Dominant Region: North America
North America accounted for 42% of the global Biologics CDMO market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects the world's largest biopharmaceutical industry, the deepest biologics pipeline, strong demand for domestic manufacturing, and substantial CDMO capacity, particularly in the United States. North America hosts the headquarters and major operations of leading developers and CDMOs and is the focus of intense capacity investment and reshoring, exemplified by Lonza's USD 1.2 billion acquisition of the large-scale Vacaville, California site, Fujifilm Biotechnologies' new Holly Springs, North Carolina facility anchored by Johnson & Johnson and Regeneron, and Thermo Fisher's planned acquisition of a Sanofi sterile site in New Jersey. The region benefits from a robust FDA regulatory framework, strong innovation and capital, and supply-security and reshoring priorities that favor domestic manufacturing. A dense base of developers, deep demand, and accelerating investment anchor the region's continued leadership across the forecast period.
Dominant:  North America ~ 42% (Largest)
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Biologics CDMO market. The region's elevated CAGR is driven by large-scale capacity expansion, competitive cost structures, a growing domestic biopharmaceutical industry, and strong government support across South Korea, China, India, Singapore, and Japan. Samsung Biologics has expanded to 784,000 liters with its fifth plant and is reviewing a sixth, WuXi Biologics has opened a large new Singapore facility, and Syngene International is expanding its footprint, while Lotte Biologics and others add capacity. The region combines world-scale mammalian manufacturing, integrated CRDMO models, and cost advantages that attract global outsourcing, alongside rising domestic demand and biosimilar production. Despite geopolitical and trade uncertainties affecting some manufacturers, the scale of investment, cost competitiveness, and government support position Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 42% of the global Biologics CDMO market revenue in 2025. The United States dominates on the strength of the world's largest biopharmaceutical industry, the deepest biologics pipeline, a robust FDA framework, strong capital, and accelerating capacity investment and reshoring, while Canada contributes through specialized manufacturing and development capacity.
Europe
Europe is a large and advanced regional market, led by Switzerland, Germany, the United Kingdom, Ireland, and Denmark. Growth is anchored by major CDMOs such as Lonza, Boehringer Ingelheim, Rentschler Biopharma, and Fujifilm Diosynth's Hillerod site, supported by strong manufacturing infrastructure, the EMA regulatory framework, and significant capacity investment across the region.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by large-scale capacity expansion, cost competitiveness, a growing domestic biopharmaceutical industry, and government support across South Korea, China, India, Singapore, and Japan. Samsung Biologics, WuXi Biologics, Syngene International, and Lotte Biologics anchor world-scale mammalian manufacturing and integrated CRDMO models that attract global outsourcing.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging contributor. Growing local biopharmaceutical demand, expanding healthcare access, and interest in regional manufacturing and supply security are creating early opportunities, while partnerships, technology transfer, and biosimilar production gradually build capacity across these markets.
 
Biologics CDMO Market Competitive Landscape
The Biologics CDMO market is classified as Moderately Concentrated. A group of large-scale leaders, including Lonza, Samsung Biologics, WuXi Biologics, and Catalent, holds a substantial share of global capacity and revenue, supported by world-scale facilities and integrated service offerings, while a broad field of specialized and regional providers, including Thermo Fisher, Fujifilm Diosynth, Boehringer Ingelheim, AGC Biologics, Rentschler Biopharma, and Syngene, competes across modalities, scales, and geographies, keeping the long tail of the market fragmented and competitive.
The competitive landscape can be evaluated across the following dimensions:
• Market concentration: Moderately concentrated, with a few world-scale leaders alongside a broad, fragmented field of specialized and regional CDMOs.
• Leading players: Lonza, Samsung Biologics, WuXi Biologics, and Catalent anchor the top tier through scale, capacity, and integrated services.
• Geographic reach: Leaders operate global manufacturing networks across North America, Europe, and Asia-Pacific, with reshoring and capacity investment reshaping footprints.
• Service portfolio strength: Top players offer integrated development, manufacturing, fill-finish, and analytical services across mammalian and microbial platforms.
• Capacity and scale: Large-scale bioreactor capacity, exemplified by Samsung's 784,000 liters and Lonza's Vacaville site, is a decisive competitive asset.
• Strategic partnerships: Long-term supply agreements with major pharma and biotech, such as Fujifilm's agreements with Regeneron and Johnson & Johnson, underpin growth.
• M&A activity: Active consolidation, including Novo Holdings' USD 16.5 billion acquisition of Catalent and Lonza's USD 1.2 billion Vacaville purchase.
• Manufacturing capabilities: Mammalian and microbial expertise, single-use and intensified bioprocessing, ADC conjugation, and emerging continuous manufacturing.
• Innovation focus: High-titer processes, continuous bioprocessing under ICH Q13, integrated CRDMO models, ADC and cell-and-gene capacity, and digital biomanufacturing.
 
Biologics CDMO Market Recent Developmental Activities
In December 2024, Novo Holdings, completed its USD 16.5 billion acquisition of Catalent, after which Novo Nordisk acquired three Catalent fill-finish sites for USD 11 billion while Catalent continued to operate as a CDMO. Strategic significance: Marked the largest consolidation in the CDMO sector and reshaped global fill-finish capacity dynamics.
In 2024, Lonza Group AG, acquired Genentech's large-scale Vacaville, California biologics manufacturing site from Roche for USD 1.2 billion, adding total bioreactor capacity of about 330,000 liters, and committed CHF 500 million to upgrade the plant. Strategic significance: Substantially expanded Lonza's large-scale mammalian capacity and strengthened its commercial-manufacturing leadership.
Biologics CDMO Market Segmentation
Biologics CDMO Market by Product Type
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Antibody-Drug Conjugates
• Cell and Gene Therapy Products
• Other Biologics
Biologics CDMO Market by Service Type
• Contract Manufacturing
• Contract Development
• Analytical and Quality Services
• Fill-Finish and Packaging
Biologics CDMO Market by Source
• Mammalian
• Microbial
• Other Expression Systems
Biologics CDMO Market by Indication
• Oncology
• Autoimmune and Inflammatory
• Infectious Diseases
• Metabolic
• Others
Biologics CDMO Market by Scale of Operation
• Clinical Scale
• Commercial Scale
Biologics CDMO Market by Geography
• North America Biologics CDMO Market
▪ United States Biologics CDMO Market Size in USD million (2023-2034)
▪ Canada Biologics CDMO Market Size in USD million (2023-2034)
▪ Mexico Biologics CDMO Market Size in USD million (2023-2034)
• Europe Biologics CDMO Market
▪ Germany Biologics CDMO Market Size in USD million (2023-2034)
▪ United Kingdom Biologics CDMO Market Size in USD million (2023-2034)
▪ France Biologics CDMO Market Size in USD million (2023-2034)
▪ Italy Biologics CDMO Market Size in USD million (2023-2034)
▪ Spain Biologics CDMO Market Size in USD million (2023-2034)
▪ Rest of Europe Biologics CDMO Market Size in USD million (2023-2034)
• Asia-Pacific Biologics CDMO Market
▪ China Biologics CDMO Market Size in USD million (2023-2034)
▪ Japan Biologics CDMO Market Size in USD million (2023-2034)
▪ India Biologics CDMO Market Size in USD million (2023-2034)
▪ South Korea Biologics CDMO Market Size in USD million (2023-2034)
▪ Australia Biologics CDMO Market Size in USD million (2023-2034)
▪ Rest of Asia-Pacific Biologics CDMO Market Size in USD million (2023-2034)
• Rest of the World (RoW) Biologics CDMO Market
▪ Middle East Biologics CDMO Market Size in USD million (2023-2034)
▪ Africa Biologics CDMO Market Size in USD million (2023-2034)
▪ South America Biologics CDMO Market Size in USD million (2023-2034)
Key Takeaways from the Biologics CDMO Market Report Study
• Market size analysis for the current biologics CDMO market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global biologics CDMO market.
• Various opportunities available for competitors in the biologics CDMO market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current biologics CDMO market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for biologics CDMO market growth in the future?
Target audience who can benefit from this biologics CDMO market report study 
• Biologics CDMO product providers
• Research organizations and consulting companies
• Biologics CDMO-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in biologics CDMO
• Various end-users who want to know more about the biologics CDMO market and the latest technological developments in the biologics CDMO market.

Frequently Asked Questions
Q1. What is the growth rate of the Biologics CDMO market?
The Biologics CDMO market is projected to expand at a CAGR of 11.7% during the forecast period from 2026-2034.
Q2. What is the market size of the Biologics CDMO market?
The Biologics CDMO market is estimated at USD 23 billion in 2025 and is projected to reach USD 62.23 billion by 2034. 
Q3. Which region dominates the Biologics CDMO market?
North America dominated the Biologics CDMO market with a 42% share of global revenue in 2025, supported by the world's largest biopharmaceutical industry, the deepest biologics pipeline, a robust regulatory framework, and accelerating capacity investment and reshoring. Asia-Pacific is the fastest-growing region over the forecast period, led by large-scale expansion in South Korea, China, India, and Singapore.
Q4. What are the key drivers of the Biologics CDMO market?
The principal drivers are the expanding biologics and advanced-modality pipeline; rising outsourcing, now 40% of pharmaceutical manufacturing; the rising global cancer burden, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050; the growth of biosimilars; large-scale capacity investment and consolidation; and the reliance of emerging biotechnology companies on CDMOs.
Q5. Who are the major players in the Biologics CDMO market?
The major players include Lonza Group AG, Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Catalent, Inc., Thermo Fisher Scientific Inc., FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim (BioXcellence), AGC Biologics, Rentschler Biopharma SE, and Syngene International Limited, among other active providers profiled in the Competitive Landscape section. Lonza, Samsung Biologics, WuXi Biologics, and Catalent lead through world-scale capacity and integrated services.